In vivo measurement of the affinity and density of metabotropic glutamate receptor subtype 1 in rat brain using18F-FITM in small-animal PET

Journal of Nuclear Medicine

Volumn 53, Issue 10, 2012, Pages 1601-1607

  Yamasaki, Tomoteru ^a,b   Fujinaga, Masayui ^a   Kawamura, Kazunori ^a   Yui, Joji ^a   Hatori, Akiko ^a   Ohya, Tomoyuki ^a   Xie, Lin ^a   Wakizaka, Hidekatsu ^a   Yoshida, Yuichiro ^c   Fukumura, Toshimitsu ^a   Zhang, Ming Rong ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c 141 0032   (Japan)

Author keywords

18F FITM; BMAX; BPND; Kd; mGluR1

Indexed keywords

4 FLUORO N [4 [6 (ISOPROPYLAMINO)PYRIMIDIN 4 YL] 1,3 THIAZOL 2 YL] N METHYLBENZAMIDE F 18; METABOTROPIC RECEPTOR 1; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BRAIN REGION; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BINDING SITE; DRUG RECEPTOR BINDING; HIPPOCAMPUS; IN VIVO STUDY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; THALAMUS;

ANIMALS; BENZAMIDES; BINDING SITES; BRAIN; KINETICS; LIGANDS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; THIAZOLES;

EID: 84867050114     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.105908     Document Type: Article

References (40)

1. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl). 2005;179:4-29. (Pubitemid 40576690)
2. Ferraguti F, Crepaldi L, Nicoletti F. Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol Rev. 2008;60:536-581.
3. Zhou M, Xu W, Liao G, Bi X, Baudry M. Neuroprotection against neonatal hypoxia/ischemia-induced cerebral cell death by prevention of calpain-mediated mGluR1alpha truncation. Exp Neurol. 2009;218:75-82.
4. De Vry J, Horvath E, Schreiber R. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu1 receptor antagonist BAY 36-7620. Eur J Pharmacol. 2001;428:203-214. (Pubitemid 33000142)
5. Kohara A, Takahashi M, Yatsugi S, et al. Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res. 2008;1191:168-179.
6. Moroni F, Attucci S, Cozzi A, et al. The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death. Neuropharmacology. 2002;42:741-751. (Pubitemid 34518274)
7. Murotomi K, Takagi N, Takayanagi G, Ono M, Takeo S, Tanonaka K. mGluR1 antagonist decreases tyrosine phosphorylation of NMDA receptor and attenuates infarct size after transient focal cerebral ischemia. J Neurochem. 2008;105:1625-1634. (Pubitemid 351678489)
8. Szydlowska K, Kaminska B, Baude A, Parsons CG, Danysz W. Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. Eur J Pharmacol. 2007;554:18-29. (Pubitemid 44820044)
9. Kaneda K, Tachibana Y, Imanishi M, et al. Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys. Eur J Neurosci. 2005;22:3241-3254. (Pubitemid 43002007)
10. Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull. 2006;69:318-326.
11. Ossowska K, Wardas J, Pietraszek M, Konieczny J, Wolfarth S. The striopallidal pathway is involved in antiparkinsonian-like effects of the blockade of group I metabotropic glutamate receptors in rats. Neurosci Lett. 2003;342:21-24. (Pubitemid 36513900)
12. Vernon AC, Croucher MJ, Dexter DT. Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model. Neuroreport. 2008;19:475-478. (Pubitemid 351301609)
13. Ribeiro FM, Paquet M, Ferreira LT, et al. Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease. J Neurosci. 2010;30:316-324.
14. 18F]fluoro-3-pyridyl)- 4-(2-isopropyl-1-oxo- isoindoline-5-yl)-5- methyl-1H-1,2,3-triazole, a PET ligand for imaging the metabotropic glutamate receptor type 1 in rat and monkey brains. J Neurochem. 2012;121:115-124.
15. 18F]fluoro-3-pyridyl)-5-methyl-1H-1,2,3-triazol-4-yl] quinoline for positron emission tomography imaging of the metabotropic glutamate receptor type 1 in brain. Bioorg Med Chem. 2011;19:102-110.
16. 18F]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse. 2011;65:125-135.
17. 11C] YM-202074 as a PET ligand for imaging the metabotropic glutamate receptor type 1. Nucl Med Biol. 2010;37:615-624.
18. 18F]fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]- 1,3-thiazol-2- yl]-N- methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1. Bioorg Med Chem Lett. 2011;21: 2998-3001.
19. Saijo T, Maeda J, Okauchi T, et al. Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter. Int J Neuropsychopharmacol. 2009;12:1021-1032.
20. Tai YC, Ruangma A, Rowland D, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med. 2005;46:455-463. (Pubitemid 43093155)
21. Yang Y, Tai YC, Siegel S, et al. Optimization and performance evaluation of the microPET II scanner for in vivo small-animal imaging. Phys Med Biol. 2004;49: 2527-2545. (Pubitemid 38967943)
22. Fowler JS, Volkow ND, Wang GJ, Ding YS, Dewey SL. PET and drug research and development. J Nucl Med. 1999;40:1154-1163. (Pubitemid 29315508)
23. Wang J, Maurer L. Positron emission tomography: applications in drug discovery and drug development. Curr Top Med Chem. 2005;5:1053-1075. (Pubitemid 41582120)
24. Satoh A, Nagatomi Y, Hirata Y, et al. Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]- N-methy lbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist. Bioorg Med Chem Lett. 2009;19:5464-5468.
25. 18F-FEDAC: PET of the monkey brain and imaging of translocator protein (18 kDa) in the infarcted rat brain. J Nucl Med. 2010;51:1301-1309.
26. 11C]FTIMD). Nucl Med Biol. 2010;37:625-635.
27. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
28. 11C] raclopride binding to D2-dopamine receptors studied by PET-a comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 1989;9:696-708.
29. Sakiyama Y, Saito M, Inoue O. Acute treatment with pentobarbital alters the kinetics of in vivo receptor binding in the mouse brain. Nucl Med Biol. 2006;33:535-541. (Pubitemid 43729847)
30. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27: 1533-1539. (Pubitemid 47301451)
31. Fotuhi M, Sharp AH, Glatt CE, et al. Differential localization of phosphoinositide-linked metabotropic glutamate receptor (mGluR1) and the inositol 1,4,5-trisphosphate receptor in rat brain. J Neurosci. 1993;13:2001-2012. (Pubitemid 23113412)
32. 18F]FITM. Eur J Nucl Med Mol Imaging. 2012;39:632-641.
33. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15:217-227. (Pubitemid 14164735)
34. Doudet DJ, Jivan S, Ruth TJ, Holden JE. Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse. 2002;44:198-202. (Pubitemid 34303918)
35. Fischer K, Sossi V, Schmid A, et al. Noninvasive nuclear imaging enables the in vivo quantification of striatal dopamine receptor expression and raclopride affinity in mice. J Nucl Med. 2011;52:1133-1141.
36. Holden JE, Jivan S, Ruth TJ, Doudet DJ. In vivo receptor assay with multiple ligand concentrations: an equilibrium approach. J Cereb Blood Flow Metab. 2002;22:1132-1141. (Pubitemid 35006806)
37. Fujinaga M, Yamasaki T, Yui J, et al. Synthesis and evaluation of novel radio-ligands for positron emission tomography imaging of metabotropic glutamate receptor subtype 1 (mGluR1) in the brain. J Med Chem. 2012;55:2342-2352.
38. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
39. Kaneda K, Imanishi M, Nambu A, Shigemoto R, Takada M. Differential expression patterns of mGluR1 alpha in monkey nigral dopamine neurons. Neuroreport. 2003;14:947-950. (Pubitemid 36829769)
40. Roselli F, Hutzler P, Wegerich Y, Livrea P, Almeida OF. Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways. PLoS ONE. 2009;4:e6011.